Novo Holdings A/S’s AbCellera Biologics ABCL Stock Holding History

Novo Holdings A/S’s Portfolio ABCL Stock Details ABCL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-652,529	Closed	-$2.24M	–	28
2025 Q2	$2.24M	Sell	652,529 -474,386	-42%	-$1.18M	0.16%	28
2025 Q1	$2.51M	Hold	1,126,915	–	–	0.19%	29
2024 Q4	$3.3M	Hold	1,126,915	–	–	0.2%	31
2024 Q3	$2.93M	Hold	1,126,915	–	–	0.15%	34
2024 Q2	$3.34M	Hold	1,126,915	–	–	0.18%	35
2024 Q1	$5.1M	Hold	1,126,915	–	–	0.35%	31
2023 Q4	$6.43M	Hold	1,126,915	–	–	0.4%	31
2023 Q3	$5.18M	Hold	1,126,915	–	–	0.38%	32
2023 Q2	$7.28M	Hold	1,126,915	–	–	0.56%	34
2023 Q1	$8.5M	Hold	1,126,915	–	–	0.56%	38
2022 Q4	$11.4M	Hold	1,126,915	–	–	0.71%	37
2022 Q3	$11.1M	Hold	1,126,915	–	–	0.53%	33
2022 Q2	$12M	Buy	+1,126,915	New	+$9.54M	0.59%	31
2021 Q3	–	Sell	-422,382	Closed	-$9.29M	–	50
2021 Q2	$9.29M	Buy	+422,382	New	+$11.6M	0.41%	37

Other funds holding ABCL

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Novo Holdings A/S's ABCL Position: Q3 2025 in Review

Novo Holdings A/S sold out of AbCellera Biologics (ABCL) in Q3 2025, closing a stake of 652,529 shares — an estimated $2.24M sold.

Novo Holdings A/S first reported a position in ABCL in Q2 2021 and held it in 14 quarters. The position peaked at $12M in Q2 2022. 141 funds tracked by Wall St. Rank hold ABCL as of Q3 2025.

Novo Holdings A/S reported no remaining AbCellera Biologics position as of Q3 2025 after selling out during the quarter.
Novo Holdings A/S sold 652,529 AbCellera Biologics shares in Q3 2025, an estimated $2.24M.
Novo Holdings A/S first reported a position in AbCellera Biologics in Q2 2021 and held it in 14 quarters.
Novo Holdings A/S's AbCellera Biologics position peaked at $12M in Q2 2022.
141 funds tracked by Wall St. Rank held AbCellera Biologics as of Q3 2025.

Based on Novo Holdings A/S's 13F filing for Q3 2025, filed 14 Nov 2025.